Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Ascletis Doses First Patient in China Trial of THRβ Agonist for NASH

publication date: Oct 5, 2022

Hangzhou Ascletis has dosed the first patient in a Phase II trial of its oral thyroid hormone receptor β (THRβ) agonist in patients with liver biopsy-proven non-alcoholic steatohepatitis (NASH). THRβ agonists have been effective in reducing low density lipoprotein, triglyceride and hepatic steatosis in humans. By promoting fatty acid breakdown and stimulating mitochondrial biogenesis, THRβ helps to reduce lipotoxicity and improve liver function, thereby reducing liver fat. Ascletis said the ASC41 trial is currently the most advanced 52-week Phase II study started by a China biotech for liver biopsy-proven NASH patients. More details....

Stock Symbol: (HK: 1672)

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital